Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CFB | P00751 | 1/20 | 0.31 |
| ▸ | POLR1A | O95602 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23746672 | 1.00 | POLB (0.39) | POLBL3MBTL1CHRM3TDP1RAB9A | |
| SCHEMBL16285866 | 1.00 | POLB (0.39) | POLBL3MBTL1CHRM3TDP1RAB9A | |
| SCHEMBL8274569 | 0.94 | L3MBTL1 (0.45) | POLBL3MBTL1CHRM3TDP1KMT2A | |
| SCHEMBL438746 | 0.94 | L3MBTL1 (0.45) | POLBL3MBTL1CHRM3TDP1KMT2A | |
| SCHEMBL105162 | 0.94 | L3MBTL1 (0.45) | POLBL3MBTL1CHRM3TDP1KMT2A | |
| SCHEMBL20088236 | 0.85 | — | — | |
| SCHEMBL17818890 | 0.85 | — | — | |
| SCHEMBL9683032 | 0.85 | — | — | |
| SCHEMBL22473381 | 0.84 | PKM (0.41) | POLBL3MBTL1CHRM3CYP1A2LMNA | |
| SCHEMBL4381935 | 0.84 | PKM (0.41) | POLBL3MBTL1CHRM3CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | claimed |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4198017-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Academy of Military Medical Sciences (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023107606-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183168-A1 | IONIZABLE LIPIDS AND COMPOSITIONS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| EP-0429984-B1 | Indole derivatives | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5124324-A | Psychological disorders, 5-hydroxy tryptamine antagonists | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-06-23 | — | — | US | disclosed |
| EP-0429984-A2 | Indole derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | POLB 4196/4885L3MBTL1 1477/4885CHRM3 4668/4885 |
| US-20230303494-A1 | BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | POLB 3163/4885L3MBTL1 353/4885CHRM3 4482/4885 |
| US-20230183168-A1 | IONIZABLE LIPIDS AND COMPOSITIONS AND USES THEREOF | SLC10A1, PYGL, FABP1 | POLB 62/4885L3MBTL1 544/4885CHRM3 3244/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | POLB 578/4885L3MBTL1 4285/4885CHRM3 179/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | POLB 1397/4885L3MBTL1 2640/4885CHRM3 2330/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | POLB 578/4885L3MBTL1 4285/4885CHRM3 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.